Philips CPAP Cancer Lawsuit News

The Phillips Sleep Apnea Machine Recall And Replace Affects Mostly US Owners

Users of the Phillips DreamStation could face a medical nightmare and should see a lung cancer specialist immediately

Thursday, September 9, 2021 - Beginning this month, September 2021, Dutch company Royal Phillips (RP), the makers of the defective Phillips brand of CPAP sleep apnea devices and ventilators, will start implementing a solution to the life-threatening problems the machines have created. The company, domiciled in The Netherlands, will start repairing first-generation Phillips DreamStation devices sold in the United States. The recall and repair operations affect those in the United States more than other countries. US sales account for more than half of all DreamStation sales, according to a recent press release. According to RP, "The vast majority (>80%) of the registered affected devices in the US to date are in the first-generation DreamStation product family." The Phillips sleep apnea machines in question have been leaching toxic particles, gasses, and chemicals into the airflow, directly into the mask, and inhaled into the lungs. People that have developed lung disease have filed Phillips CPAP cancer lawsuits claiming that the company was negligent in selling the defective device.

It is important that every Phillips sleep apnea machine owner visit the company's website and register their product on the dedicated recall notification website, and speak with a Phillips CPAP lawyer to see if they qualify to file a claim against the company for selling a defective product without an adequate warning. If anyone is on the fence and thinks that the problems with the CPAP device are being exaggerated or overblown, here is what the US Food and Drug Administration has to say on the issue. The FDA warns, " The polyester-based polyurethane (PE-PUR) sound abatement foam, which is used to reduce sound and vibration in these affected devices, may break down and potentially enter the device's air pathway. If this occurs, black debris from the foam or certain chemicals released into the device's air pathway may be inhaled or swallowed by the person using the device."

Lung Cancer is a definite possibility for people that have used the machine regularly because the polyurethane foam used as a noise inhibitor in the defective Philips sleep apnea machines and ventilators is made of toluene diisocyanate which is known to cause cancer. People should immediately see a lung cancer specialist whether or not they are exhibiting symptoms of cancer. Phillips CPAP cancer victims could walk around with the disease for ten years or more before ever being aware they contracted the disease. Some forms of lung cancer have a latency period of ten years or more, during which time the disease can metastasize (spread) to other parts of the body or bloodstream making it difficult to treat. Lung health anomalies usually precede lung cancer. Users of the sleep apnea machines could develop bronchitis, asthma, emphysema, pneumonia, or other lung disorders first. It is important to continue to treat sleep apnea, but even more so to take the Phillips CPAP lung cancer risks seriously. Waiting too long to diagnose and treat lung cancer could be a death sentence.

More Recent Philips CPAP Cancer Lawsuit News:

Lawyers for CPAP Cancer Lawsuits

We will represent all persons in involved in a BiPAP or CPAP cancer lawsuit on a contingency basis, meaning there are never any legal fees unless we win compensation in your case. Anyone who developed cancer or another serious side effect as a result of using a Philips CPAP sleep apnea machine or ventilator in --or is a family member of such a person--is eligible to receive a free, no-obligation case review from our attorneys. Simply contact our firm through the online contact form or the chat feature and one of our Philips BiPAP cancer lawyers serving will contact you promptly to discuss your case.



Privacy Notice: This site uses cookies for advertising, analytics and to improve our site services. By continuing to use our site, you agree to our use of cookies. For more information, see our cookie and privacy policy.